Community Academic
Profiles
Mark Holodniy Info

Mark Holodniy

Profile: http://med.stanford.edu/profiles/Mark_Holodniy/
Academic Appointments
Appointment
Organization
Professor - Med Center Line
Medicine - Infectious Diseases
Graduate & Fellowship Program Affiliations
Infectious Diseases ; Medicine ;
 
Honors & Awards
Title
Organization
Date(s)
Divisional Award for Exceptional Contributions in Education in the Division of Infectious Disease
Department of Medicine
2004
Infectious Diseases Teaching Award
Division of Infectious Diseases
2004
Infectious Diseases Teaching Award
Division of Infectious Diseases
1997
HIV Program Clinical Excellence Award
Department of Veterans Affairs
2001
Administrative Appointments
Title
Organization
Start Year
End Year
Member
Medical School Faculty Senate
1999
2002
Member
Administrative Panel on Biosafety
1995
2007
Professional Education
Degree
Awarding Institution
Field of Study
Year of Graduation
BS
Seattle University
Biology
1980
MD
Northwestern University
Medicine
1985
---
Good Samaritan MC Phoenix, AZ
Internal Medicine Residency
1988
---
Stanford University
Infectious Diseases Fellowship
1990
Research Interests

My research program is currently focused in three areas: 1) translational research (HCV/HIV viral evolution and antiviral resistance prevalence and development), 2) HIV/HCV clinical trials (diagnostic assay/medical device, antiretrovirals, ARVs and immunomodulators), and 3) health services research focusing on cost effectiveness of HIV antibody and ARV resistance testing and ARV utilization and clincal outcome.

Community and International Work
Publications
  • Louie JK, Kajon AE, Holodniy M, Guardia-Labar L, Lee B, Petru AM, Hacker JK, Schnurr DP "Severe Pneumonia Due to Adenovirus Serotype 14: A New Respiratory Threat?" Clin Infect Dis 2008; More »
  • Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ, Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE, Choudhri S "Safety, Tolerability, Pharmacokinetics, and Efficacy of an Interleukin-2 Agonist Among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy." J Interferon Cytokine Res 2008; 28: 2: 89-100 More »
  • Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A "Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine." J Infect Dis 2008; 197: 6: 825-35 More »
  • Desai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M "Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy." HIV Clin Trials 2007 Sep-Oct; 8: 5: 293-302 More »
  • Hornberger J, Holodniy M, Robertus K, Winnike M, Gibson E, Verhulst E "A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy." Med Decis Making 2007 Nov-Dec; 27: 6: 789-821 More »
90 publications:   view full list